Breaking News

Evotec Acquires Central Glass Germany

Expands clinical and commercial drug substance manufacturing capabilities.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec SE has expanded its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd. Going forward, Central Glass Germany GmbH will operate as Evotec Drug Substance (Germany) GmbH (Evotec DS). The company is located on a pharmaceutical manufacturing campus in Halle/Westphalia, Germany and is operating with a team of approximately 60 chemical manufacturing expert...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters